中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (8): 626-630.doi: 10.12144/zgmfskin202508626

• 综述 • 上一篇    

获得性反应性穿通性胶原病研究进展

麦少珍1,蓝雨1,张振颖2   

  1. 1中山大学附属第八医院（深圳福田）皮肤科，广东深圳，518000；2香港大学深圳医院皮肤科，广东深圳，518000
  • 出版日期:2025-08-15 发布日期:2025-08-01

Update of acquired reactive perforating collagenosis

MAI Shaozhen1, LAN Yu1, ZHANG Zhenying2   

  1. 1 Department of Dermatology, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518000, China; 2 Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen 518000, China
  • Online:2025-08-15 Published:2025-08-01

PDF (PC)

25

摘要： 获得性反应性穿通性胶原病（acquired reactive perforating collagenosis, ARPC）是一种罕见的以变性胶原组织经表皮清除为主要特征的穿通性疾病。目前，ARPC的病因及发病机制尚不明确，且尚无治疗的金标准。本文对ARPC的临床表现、流行病学、病因与发病机制、诊断及治疗进行综述，重点关注ARPC发病机制的新进展、皮肤镜表现、生物制剂及小分子药物的应用。

关键词: 获得性反应性穿通性胶原病, 2型炎症, 皮肤镜, 生物制剂, 小分子药物

Abstract: Acquired reactive perforating collagenosis (ARPC) is a rare perforating dermatosis characterized by transepidermal elimination of altered collagen fibers. The etiology and pathophysiology of ARPC remain elusive, and there is no gold standard for its treatment. This study comprehensively reviews the clinical manifestations, epidemiology, etiology, pathophysiology, diagnosis, and treatment of ARPC, with a focus on recent advances in pathophysiology, dermoscopic findings, and the application of biologic agents and small molecule drugs.

Key words: acquired reactive perforating collagenosis, type 2 inflammation, dermatoscope, biologic agents, small molecule drugs